• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续静脉输注去铁胺。成人继发性血色素沉着症的治疗。

Continuous intravenous deferoxamine infusion. Treatment of secondary hemochromatosis in adults.

作者信息

Blume K G, Beutler E, Chillar R K, Fahey J L, Sharkoff D, Zia P K

出版信息

JAMA. 1978 May 19;239(20):2149-51.

PMID:642157
Abstract

Adult patients with chronic iron overload were given oral ascorbic acid and continuous intravenous infusions of deferoxamine mesylate. The dosage of deferoxamine mesylate was altered every 48 hours from 1 g/sq m/24 hr to 2 or 4 g/sq m/24 hr. The average iron mobilization was 55.6 mg per day at the 1 g/sq m/24 hr dosage level, 78.6 mg every 24 hours at the 2 g/sq m/24 hr dosage level, and 90.1 mg every 24 hours at the 4 g/sq m/24 hr dosage level. Iron mobilization was undiminished when successive 14-day courses of deferoxamine separated by six-week intervals were administered.

摘要

患有慢性铁过载的成年患者口服了抗坏血酸,并持续静脉输注甲磺酸去铁胺。甲磺酸去铁胺的剂量每48小时从1 g/平方米/24小时调整为2或4 g/平方米/24小时。在1 g/平方米/24小时的剂量水平下,平均每日铁动员量为55.6毫克;在2 g/平方米/24小时的剂量水平下,每24小时为78.6毫克;在4 g/平方米/24小时的剂量水平下,每24小时为90.1毫克。当以六周为间隔连续给予14天的去铁胺疗程时,铁动员并未减少。

相似文献

1
Continuous intravenous deferoxamine infusion. Treatment of secondary hemochromatosis in adults.持续静脉输注去铁胺。成人继发性血色素沉着症的治疗。
JAMA. 1978 May 19;239(20):2149-51.
2
Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.皮下注射去铁胺和口服维生素C对先天性再生障碍性贫血及与5q-综合征相关的难治性贫血中铁排泄的影响。
Am J Pediatr Hematol Oncol. 1982 Summer;4(2):115-23.
3
Continuous subcutaneous administration of deferoxamine in patients with iron overload.对铁过载患者持续皮下给予去铁胺。
N Engl J Med. 1977 Aug 25;297(8):418-23. doi: 10.1056/NEJM197708252970804.
4
Effect of ascorbic acid on desferrioxamine-induced urinary iron excretion in idiopathic hemochromatosis.抗坏血酸对去铁胺诱导的特发性血色素沉着症患者尿铁排泄的影响。
Acta Haematol. 1984;72(2):117-20. doi: 10.1159/000206370.
5
Long-term intraperitoneal deferoxamine for hemochromatosis.长期腹腔内注射去铁胺治疗血色素沉着症。
Am J Med. 1996 Mar;100(3):308-12. doi: 10.1016/S0002-9343(97)89489-2.
6
[Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].[铁螯合疗法(去铁胺和抗坏血酸)在血色沉着病和库利贫血中的进一步经验]
Minerva Med. 1978 Mar 17;69(13):811-21.
7
Use of subcutaneous deferoxamine in a child with hemochromatosis associated with congenital dyserythropoietic anemia, type I.皮下注射去铁胺在一名患有I型先天性红细胞生成异常性贫血相关血色素沉着症儿童中的应用。
Mayo Clin Proc. 1982 May;57(5):322-5.
8
Iron chelation therapy with deferoxamine in Cooley anemia.用去铁胺进行铁螯合疗法治疗库利贫血。
J Pediatr. 1978 Apr;92(4):643-7. doi: 10.1016/s0022-3476(78)80314-x.
9
Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
Lancet. 1977 May 7;1(8019):977-9. doi: 10.1016/s0140-6736(77)92279-6.
10
Reassessment of the use of desferrioxamine B in iron overload.去铁胺B在铁过载治疗中的应用再评估
N Engl J Med. 1976 Jun 24;294(26):1421-3. doi: 10.1056/NEJM197606242942603.

引用本文的文献

1
Preparation of 67Ga-labelled human IgG and its Fab fragments using desferoxamine as chelating agent.以去铁胺作为螯合剂制备67Ga标记的人IgG及其Fab片段。
Eur J Nucl Med. 1985;11(6-7):240-5. doi: 10.1007/BF00279077.
2
Gallium-67 scintigraphy in patients with hemochromatosis treated by deferoxamine.去铁胺治疗的血色素沉着症患者的镓-67闪烁扫描术
Ann Nucl Med. 1988 May;2(1):35-9. doi: 10.1007/BF03164584.